Somalogic Intrinsic Value Calculator – SOMALOGIC Reports Second Quarter Earnings Results for FY2023
August 27, 2023
🌥️Earnings Overview
On August 14 2023, SOMALOGIC ($NASDAQ:SLGC) released their financial results for the second quarter of FY2023, ending on June 30 2023. In comparison to the corresponding quarter a year prior, total revenue grew by 44.8% to USD 20.5 million, while net income decreased from -23.0 million to -24.8 million.
Share Price
The stock opened the day at $2.0 and closed at the same price, down by 1.9% from its previous closing price of 2.1. This increase can be attributed to their improved operational efficiency and cost control initiatives. Overall, it was a positive quarter for SOMALOGIC with strong operational performance and financial results. With their strategic investments in technology and infrastructure, they are well-positioned for further growth in the upcoming quarters. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Somalogic. More…
| Total Revenues | Net Income | Net Margin |
| 101.39 | -141.17 | -145.9% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Somalogic. More…
| Operations | Investing | Financing |
| -133.68 | 65.62 | 0.72 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Somalogic. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 585.75 | 70.59 | 2.74 |
Key Ratios Snapshot
Some of the financial key ratios for Somalogic are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| – | – | -99.1% |
| FCF Margin | ROE | ROA |
| -137.2% | -12.0% | -10.7% |
Analysis – Somalogic Intrinsic Value Calculator
At GoodWhale, we have analyzed the financials of SOMALOGIC and applied our proprietary Valuation Line to calculate a fair value of around $7.4 for a share of the company’s stock. Surprisingly, we found that the stock is currently trading at only $2.0 – which is undervalued by 73.1%. Clearly, this presents a tremendous value opportunity for investors. At GoodWhale, our mission is to help investors make smart, informed decisions when it comes to their investments. We believe that SOMALOGIC is a great opportunity for those looking to purchase undervalued, high-quality stocks – and we encourage anyone interested in taking advantage of this opportunity to do further research and consider investing in the company. More…
Peers
The biotechnology industry is growing rapidly and is becoming increasingly competitive. SomaLogic Inc is a leading player in this industry, and is up against some stiff competition from Cue Health Inc, Vynleads Inc, and Winsan (Chengdu) Medical Science and Technology Co Ltd. All of these companies are vying for a share of the biotechnology market, and each has its own unique strengths and weaknesses. SomaLogic Inc has a strong R&D department and is able to bring new products to market quickly. However, its competitors are not far behind, and are constantly innovating and introducing new products and technologies. It is important for SomaLogic Inc to stay ahead of the competition, and to continue to innovate and introduce new products and services in order to maintain its position as a leader in the biotechnology industry.
– Cue Health Inc ($NASDAQ:HLTH)
Cue Health Inc is a diagnostics company that develops, manufactures, and markets point-of-care molecular tests. The company’s products are used to detect and manage a variety of conditions, including infectious diseases, cancer, and genetic disorders. Cue Health Inc’s market cap is 528.91M as of 2022. The company’s Return on Equity is -2.34%.
– Vynleads Inc ($OTCPK:VYND)
Vynleads Inc is a lead generation company that provides businesses with access to potential customers. The company has a market cap of 3.19M as of 2022 and a return on equity of 28.69%. Vynleads Inc helps businesses generate leads through its online platform and offers a variety of lead generation services. The company has a strong focus on customer satisfaction and has a proven track record of generating quality leads.
– Winsan (Chengdu) Medical Science And Technology Co Ltd ($SHSE:600767)
Winsan (Chengdu) Medical Science And Technology Co Ltd is a medical technology company that develops and manufactures medical devices and equipment. The company has a market cap of 1.93B as of 2022 and a Return on Equity of 3.09%. Winsan (Chengdu) Medical Science And Technology Co Ltd is a medical technology company that develops and manufactures medical devices and equipment. The company has a market cap of 1.93B as of 2022 and a Return on Equity of 3.09%.
Summary
Somalogic, a healthcare company, recently announced its second quarter of FY2023 earnings results for the period ending June 30, 2023. Investors are encouraged to further analyze the company’s financial performance in order to determine the potential upside and risk involved with investing in Somalogic. This includes examining the company’s cash flow, balance sheet, and other financial metrics in order to assess Somalogic’s ability to generate returns in the future.
